Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats

Bqoqu Li, Na Li, Shujuan Wang.




Abstract

Aim:Oridonin is a new anti-tumor drug candidate with promising antitumor activity. The aim of the present study is to investigate the single- and repeated-dose pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex in rats. Methods: Rats were given single- or multiple-dose (7 days) of injectable beta-cyclodextrin-oridonin inclusion complex (single-dose: 33 mg/m2, 99 mg/m2, 296 mg/m2; repeatede-dose: 99 mg/m2 calculated as oridonin) by intravenous injection. Plasma oridonin was analyzed by LC–ESI-MS. The main pharmacokinetics parameters were calculated and compared. Results: The PK data of single-dose injectable beta-cyclodextrin-oridonin inclusion complex in rats were best fit by a three-compartment model.The terminal elimination half-life (t1/2z) of oridonin ranged from 8.72±1.14 to 10.87±2.03h. AUC (0-t) and Cmax for oridonin showed statistically significant differences (p < 0.05) between singledose and repeated dose. Conclusion: Our study has led to the view that injectable beta-cyclodextrin-oridonin inclusion complex can increase the bioavailability of oridonin in rats and is suitable for once a day dosing. However, caution should be taken when injectable beta-cyclodextrin-oridonin inclusion complex is given by i.v. repeatedly.

Key words: Pharmacokinetics; Oridonin; Beta-cyclodextrin; rats






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.